免疫检查点抑制剂的眼部不良反应:梅奥诊所经验
该单中心回顾性研究纳入2010至2020年使用免疫检查点抑制剂的996例患者,28例(2.8%)出现需眼科就诊的眼部不良反应,最常见为干眼16例(57%),其次为葡萄膜炎4例(14%)。PD-L1靶向治疗的眼表不良反应更常见,多数眼部事件可经靶向治疗控制而无需停用免疫治疗。
要点
- 免疫检查点抑制剂相关眼部不良反应发生率为2.8%,以干眼最常见。
- PD-L1靶向治疗可能更易出现眼表不良反应。
- 多数眼部不良反应可控制,仅1例全葡萄膜炎需停用免疫治疗。
核心结论
- 免疫检查点抑制剂的眼部免疫相关不良反应罕见但可能比既往估计更常见。
- PD-L1靶向检查点抑制剂可能对眼表不良反应有轻微倾向性。
- 多数眼部事件可经靶向治疗控制而无需停用延长生命的免疫治疗。
研究设计与样本
- 单中心回顾性研究,纳入2010年1月1日至2020年2月29日使用免疫检查点抑制剂的患者,共996例。
- 回顾性分析临床特征、治疗及并发全身不良反应。
主要发现
- 996例中28例(2.8%)出现需眼科就诊的眼部不良反应。
- 出现不良反应时平均年龄63岁(中位64,范围25-88)。
- 最常见 preceding 药物为帕博利珠单抗12例(43%)。
- 最常见不良反应为干眼16例(57%),其次葡萄膜炎4例(14%),另有上睑下垂和双眼复视等个案。
- 13例(46%)有随访,平均20个月(中位16,范围2-52个月),其中12例(92%)眼部不良反应控制且未停用免疫治疗。
关键数值与推荐
- 眼表不良反应在PD-L1靶向治疗中更常见。
- 基于检查点靶点的眼眶/眼附属器、葡萄膜炎或视网膜不良反应频率无显著差异。
- 1例全葡萄膜炎患者需停用检查点抑制剂。
临床怎么用
- 使用免疫检查点抑制剂的患者出现眼部症状时应考虑免疫相关不良反应。
- 多数眼部不良反应可经靶向治疗控制,无需常规停用免疫治疗。
- PD-L1靶向治疗患者需关注眼表不良反应。
局限性
- 单中心回顾性研究。
- 仅纳入需眼科就诊的眼部不良反应,可能低估总体发生率。
- 随访资料仅覆盖46%的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To investigate immune-related ophthalmic side effects of systemic checkpoint inhibitors and compare side effect frequency and requirement for cessation of immunotherapy by checkpoint target. METHODS: Patients taking immune checkpoint inhibitors at a single centre from January 1, 2010 to February 29, 2020 were retrospectively reviewed for clinical characteristics, treatments and concurrent systemic adverse effects. RESULTS: Of 996 patients, 28 (2.8%) experienced an ophthalmic side effect that came to the attention of an eye care provider. Mean age at presentation of the side effect was 63 years (median 64, range 25-88). The checkpoint inhibitor most often preceding side effects was pembrolizumab in 12 (43%). The most common side effect was dry eye in 16 (57%), followed by uveitis in 4 (14%) patients, and singular cases of ptosis and binocular diplopia, among others. Ocular surface adverse effects occurred more frequently with programmed death ligand-1 (PD-L1) targeting therapy. There were no significant differences in the frequency of orbit/ocular adnexa and uveitis or retinal side effects based on checkpoint targets. Follow-up was available in 13 (46%) patients, with mean duration of 20 months (median 16, range 2-52 months). Of these patients, the ophthalmic side effects were controlled without discontinuing therapy in 12 (92%). Checkpoint inhibitor cessation was required in one patient with panuveitis. CONCLUSION: Ophthalmic immune-related adverse events are rare but could be more common than previously estimated. PD-L1-directed checkpoint inhibitors may have a slight predilection for ocular surface adverse effects. Most ophthalmic events can be treated with targeted therapy without discontinuation of life-prolonging immunotherapy.
引用
- Fortes BH, Liou H, Dalvin LA, et al. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2020. PMID: 32830124. doi:10.1136/bjophthalmol-2020-316970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。